| Literature DB >> 27417531 |
Ann E Kurth1, Nok Chhun, Charles M Cleland, Michele Crespo-Fierro, José A Parés-Avila, John A Lizcano, Robert G Norman, Michele G Shedlin, Barbara E Johnston, Victoria L Sharp.
Abstract
BACKGROUND: Human immunodeficiency virus (HIV) disease in the United States disproportionately affects minorities, including Latinos. Barriers including language are associated with lower antiretroviral therapy (ART) adherence seen among Latinos, yet ART and interventions for clinic visit adherence are rarely developed or delivered in Spanish.Entities:
Keywords: HIV; Technology Acceptance Model; antiretroviral therapy adherence; computer-based counseling; cultural adaptation; linguistic adaptation; prevention with positives; viral load
Mesh:
Year: 2016 PMID: 27417531 PMCID: PMC4963608 DOI: 10.2196/jmir.5830
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 5.428
Figure 1Screenshots of CARE+ Spanish.
Figure 2Participant flowchart of the CARE+ Spanish computer-based counseling intervention trial, five sessions over 12 months.
Demographic characteristics of CARE+ Spanish intervention and control groups (N=433).
| Variable | CARE+ Spanish (n=226) | Control (n=207) | |||
| Male | 153 (68.0) | 143 (69.4) | .05 | ||
| Female | 56 (24.9) | 54 (26.2) | |||
| Transgender | 9 (4.0) | 1 (0.5) | |||
| Unknown | 7 (3.1) | 8 (3.8) | |||
| 46.8 (9.7) | 48.9 (9.1) | .02 | |||
| Latino | 218 (96.9) | 191 (92.7) | .20 | ||
| American Indian or Alaska Native | 12 (5.3) | 13 (6.4) | .33 | ||
| Asian | 2 (0.8) | 0 (0.0) | |||
| Black or African American | 13 (5.8) | 19 (9.2) | |||
| Native Hawaiian or other Pacific Islander | 2 (0.8) | 3 (1.5) | |||
| White | 38 (16.8) | 42 (20.4) | |||
| Other race | 151 (66.8) | 118 (57.3) | |||
| Multiple race | 3 (1.3) | 5 (2.4) | |||
| Unknown | 5 (2.2) | 7 (3.4) | |||
| No high school diploma/GED | 79 (35.0) | 72 (34.8) | .13 | ||
| High school diploma/GED only | 65 (28.8) | 75 (36.2) | |||
| More than high school | 75 (33.2) | 56 (27.1) | |||
| Unknown | 7 (3.1) | 4 (1.9) | |||
| Ever injecting drug use | 12 (5.3) | 10 (4.8) | .55 | ||
| Alcohol abuse | 44 (19.6) | 41 (19.8) | >.99 | ||
| Methamphetamine use | 12 (5.5) | 12 (6.1) | .84 | ||
| Crack/cocaine use | 24 (11.2) | 25 (12.6) | .76 | ||
| Intimate partner violence, n (%) | 16 (7.2) | — | — | ||
| Any sex past 3 months | 139 (63.8) | 124 (62.3) | .76 | ||
| Risky sexb | 35 (25.9) | 26 (21.7) | .46 | ||
| Condom use with problems | 47 (33.8) | 36 (29.0) | .43 | ||
| Any sex without condoms or with condom problems | 69 (50.7) | 56 (46.3) | .53 | ||
| Discordant sex with main partner | 8 (3.7) | 7 (3.5) | >.99 | ||
| Discordant sex with other partner | 11 (5.1) | 6 (3.1) | .46 | ||
| Adherence VAS, mean (SD) | 87.0 (22.4) | 89.6 (19.5) | .20 | ||
| VAS Scale ≥95%, n (%) | 135 (59.7) | 122 (58.9) | .92 | ||
| Missed doses, mean (SD) | 1.5 (8.0) | 1.6 (8.2) | .86 | ||
| 1 or more missed doses past 7 days, n (%) | 74 (37.2) | 64 (35.2) | .75 | ||
| 2 or more missed doses past 7 days, n (%) | 41 (20.6) | 36 (19.8) | .90 | ||
| > VAS 95% + no missed doses, n (%) | 93 (44.1) | 89 (44.9) | .92 | ||
| Log10 HIV-1 viral load, mean (SD) | 1.2 (1.8) | 1.2 (1.6) | .93 | ||
| Detectable viral load, n (%) | 78 (34.5) | 76 (36.7) | .69 | ||
| Ever told resistant virus, n (%) | 30 (13.8) | 32 (15.9) | .67 | ||
| Years since HIV diagnosis, mean (SD) | 12.6 (6.9) | 13.4 (7.3) | .23 | ||
| Depression (PHQ-9), n (%) | 35 (15.6) | 39 (18.8) | .38 | ||
a Comparisons by Fisher exact test or Wilcoxon rank sum test; All categorical tests performed without the unknown category.
b Did not use a condom with either main partner or other partner.
Figure 3Adjusted mean values or proportions by time and treatment condition of the total sample and those with detectable viral loads at baseline (BL) for (a) log10 viral load, (b) undetectable viral load, (c) visual analog scale for ART adherence, and (d) sexual transmission risk. Whiskers represent 95% confidence intervals.
Figure 4Mean differences or odds ratios contrasting CARE+ and control conditions at each follow-up time point, and baseline (BL) and final time points within each condition, for (a) log10 viral load, (b) undetectable viral load, (c) visual analog scale for ART adherence, and (d) sexual transmission risk. Whiskers represent 95% confidence intervals.